摘要
胰腺癌目前仍然是临床非常棘手的问题，但在一些胰腺外科中心通过手术切除改善了胰腺癌的预后。目前已有结果提示新辅助治疗对胰腺癌患者安全，且能够显著提高手术切除率。但新辅助治疗与手术治疗、术后辅助治疗及姑息治疗相比较其疗效如何，到目前为止，尚缺少高质量的循证医学证据，也没有关于胰腺癌新辅助化疗或放化疗与外科手术后系统化疗间比较的随机对照研究。需要设计完善的随机对照研究对比新辅助化疗和手术治疗，以此来评价新辅助化疗在胰腺癌多种治疗方案中的价值。
Surgical treatment has improved the prognosis of resectable pancreatic cancer considerably despite the generally aggressive behavior of its malignancy. Neoadjuvant therapy for pancreatic cancer has been shown effective in improving a survival benefit. Few prospective randomized controlled clinical trials （RCTs） on the use of neoadjuvant chemotherapy and chemoradiation has been done tp show the survival advantage of systemic chemotherapy （5-FU/FA or gemcitabine） following surgical resection. Up to now, there is no high- level evidence of any benefit deriving from neoadjuvant chemo therapy for pancreatic cancer. Well designed trials are needed to compare neoadjuvant chemotherapy with surgery to judge the value of neoadjuvant chemo- therapy in multimodal treatment concepts of pancreatic cancer.
出处
《国际外科学杂志》
2009年第5期335-338,共4页
International Journal of Surgery
关键词
胰腺癌
新辅助治疗
化疗
临床
pancreatic cancer
neoadjuvant chemotherapy
